Qiagen and Abbott extend distribution agreement:
This article was originally published in Clinica
Executive Summary
Diagnostic firms Qiagen and Abbott Laboratories have extended their distribution agreement for Qiagen's RealArt molecular diagnostic tests. Under the revised agreement, Abbott will have non-exclusive distribution rights to certain Qiagen products, including infectious disease tests for hepatitis B virus (HBV), Epstein-Barr virus (EBV), Varicella-Zoster virus (VZM), Parvo B19 virus, cytomegalovirus (CMV), herpes simplex complex and enterovirus. The PCR assays were developed by artus GmbH, a company acquired by Qiagen in May, and use Applied Biosystem's detection instrument. Qiagen is based in Venlo, the Netherlands.
You may also be interested in...
There’s ‘No Silver Bullet’ For Making Medicines Packaging Sustainable
There’s no simple answer to the question of how to make medicines packaging sustainable, says international recycling consultancy and Veolia Group subsidiary Circpack. “Manufacturers need to assess what works best for them, and recyclers will do the same,” Circpack analyst and circular packaging expert Filipe Vieira de Castro tells HBW Insight in this exclusive Q&A. “The best thing we can all do is put effort into finding common ground between systems, which comes down to better understanding the complexities between them.”
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.